What is the 13F Pro Quality Score for SNDX?

13F Pro ranks Syndax Pharmaceuticals Inc (SNDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SNDX's current score at https://13fpro.ai/research/SNDX (free sign-up required for the full ranking).

Which hedge funds own the most SNDX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SNDX include BlackRock,, Kynam Capital Management,, GOLDMAN SACHS GROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SNDX as soon as new 13F filings post.

Where does 13F Pro source SNDX data?

All Syndax Pharmaceuticals Inc fundamentals and ownership data come directly from SEC EDGAR. Syndax Pharmaceuticals Inc files with the SEC under CIK 1395937. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SNDX in?

Syndax Pharmaceuticals Inc (SNDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SNDX research updated on 13F Pro?

SNDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Syndax Pharmaceuticals Inc(SNDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1395937 SNDX stock profile & AI dashboard →

13F Pro Quality Score

30.0/100

Rank #2,378 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

6.2/100

Balance Sheet

3.4/100

Earnings Quality

30.0/100

Free Cash Flow

5.2/100

Institutional Flow

48.6/100

Revenue Scale

22.5/100

Dilution Risk

6.9/100

SNDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Syndax Pharmaceuticals Inc (SNDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SNDX at 30.0/100 on a 32-signal composite quality model, placing it at rank #2,378 of 2,879 stocks — the bottom half of the AI-ranked universe. SNDX scores in the top quartile across revenue growth (99.1). Areas of concern include balance sheet strength (3.4) and free cash flow (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Syndax Pharmaceuticals Inc reports quarterly revenue of $64.9M, net income of $-42.7M, free cash flow of $-50.3M. Top institutional holders of SNDX by reported 13-F value include BlackRock,, Kynam Capital Management,, GOLDMAN SACHS GROUP, based on the most recent SEC filings. SNDX trades on the Nasdaq exchange and files with the SEC under CIK 1395937. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Syndax Pharmaceuticals Inc directly from SEC EDGAR. Syndax Pharmaceuticals Inc's 13F Pro composite quality score has ranged between 8 and 91 since 2021, currently 30.0 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Syndax Pharmaceuticals Inc

Quirks, history, and lore behind SNDX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on oncology.
2
The Numbers
A small-cap with no product revenue yet — it runs on grants, partnerships, and the eternal optimism of biotech investors funding expensive cancer trials.
3
The History
Founded in the early 2000s, the company has spent two decades building a pipeline around a class of targets called epigenetic regulators, which control how genes get switched on and off in tumor cells.
4
The Secret
Its lead focus is on menin inhibitors — a relatively novel mechanism targeting certain leukemias driven by specific genetic mutations, putting it in a small club of companies chasing this approach.
5
The Lore
The company's pipeline also includes revumenib, an investigational menin inhibitor studied in acute leukemia patients who have run out of other options — a drug that drew genuine buzz at major hematology conferences.
6
The Giveaway
Ticker SNDX, headquartered in Watertown, MA — this is Syndax Pharmaceuticals, the epigenetics-focused oncology shop swinging for a cure one mutated leukemia cell at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$64.9M

Net Income

Q1 2026

$-42.7M

Free Cash Flow

Q1 2026

$-50.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$23.7MFY 2024

FY21 $139.7MFY22 $0.00FY23 $0.00FY24 $23.7M

Net Income

-52.3% YoY

$-318.8MFY 2024

FY21 $24.9MFY22 $-149.3MFY23 $-209.4MFY24 $-318.8M

Operating Income

-47.7% YoY

$-339.7MFY 2024

FY21 $26.2MFY22 $-151.8MFY23 $-230.0MFY24 $-339.7M

EPS (Diluted)

-24.8% YoY

$-3.72FY 2024

FY21 $0.46FY22 $-2.46FY23 $-2.98FY24 $-3.72

Total Assets

+18.3% YoY

$724.8MFY 2024

FY21 $449.7MFY22 $497.2MFY23 $612.9MFY24 $724.8M

Total Debt

$681.6MFY 2024

FY21 —FY22 —FY23 $0.00FY24 $681.6M

Op. Cash Flow

-71.2% YoY

$-274.9MFY 2024

FY21 $29.1MFY22 $-133.7MFY23 $-160.6MFY24 $-274.9M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$23.7M	$0.00	$0.00 -100.0%	$139.7M +9109.6%	$1.5M +0.0%	$1.5M
Net Income	$-318.8M -52.3%	$-209.4M -40.2%	$-149.3M -699.1%	$24.9M +134.1%	$-73.2M -30.5%	$-56.0M
Operating Income	$-339.7M -47.7%	$-230.0M -51.5%	$-151.8M -678.8%	$26.2M +136.7%	$-71.4M -24.1%	$-57.5M
EPS (Diluted)	$-3.72 -24.8%	$-2.98 -21.1%	$-2.46 -634.8%	$0.46 +124.6%	$-1.87 -1.6%	$-1.84
Total Assets	$724.8M +18.3%	$612.9M +23.3%	$497.2M +10.6%	$449.7M +49.6%	$300.6M +373.2%	$63.5M
Total Debt	$681.6M	$0.00	—	—	—	—
Operating Cash Flow	$-274.9M -71.2%	$-160.6M -20.1%	$-133.7M -558.9%	$29.1M +140.9%	$-71.3M -40.8%	$-50.6M

AI Insight: SNDX Ratio Trends

Operating losses are narrowing sharply — Q1 2026 operating margin improved to -52.7% from a -183.9% trough in Q2 2025 — but leverage surged to 16.67x D/E, creating a critical funding overhang.

• Operating margin improved dramatically from -183.9% in Q2 2025 to -52.7% in Q1 2026, suggesting accelerating revenue ramp or cost discipline.

• ROA improved from -48.2% in Q2 2025 to -36.1% in Q1 2026, indicating more efficient asset utilization as losses narrow.

• ROIC recovered from -97.8% in Q3 2024 to -18.6% in Q1 2026, a substantial multi-quarter improvement in capital efficiency.

• D/E ratio surged from 2.37 in Q4 2024 to 16.67 in Q1 2026, reflecting heavy debt-financed operations throughout the period.

⚠ D/E of 16.67x in Q1 2026 is dangerously elevated; any revenue shortfall could impair the company's ability to service debt.

⚠ TTM operating margin of -102.9% versus Q1 2026's -52.7% suggests prior quarters weighed heavily — sustainability of improvement is unconfirmed.

⚠ ROE data is unavailable for Q3 2025 through Q1 2026 — equity base changes warrant close monitoring given rising leverage.

Get alerted when SNDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Syndax Pharmaceuticals Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SNDX

BlackRock, Inc.
$192.8M8,254,426 sh
Kynam Capital Management, LP
$188.1M8,050,959 sh
GOLDMAN SACHS GROUP INC
$116.7M4,996,787 sh
STATE STREET CORP
$103.5M4,430,076 sh
BANK OF AMERICA CORP /DE/
$99.3M4,249,836 sh
VANGUARD CAPITAL MANAGEMENT LLC
$89.3M3,822,579 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$88.3M3,779,900 sh
Eversept Partners, LP
$67.4M2,885,622 sh
KINGDON CAPITAL MANAGEMENT, L.L.C.
$58.4M2,500,000 sh
Hood River Capital Management LLC
$55.0M2,354,285 sh

Fund	Value	Shares
BlackRock, Inc.	$192.8M	8,254,426
Kynam Capital Management, LP	$188.1M	8,050,959
GOLDMAN SACHS GROUP INC	$116.7M	4,996,787
STATE STREET CORP	$103.5M	4,430,076
BANK OF AMERICA CORP /DE/	$99.3M	4,249,836
VANGUARD CAPITAL MANAGEMENT LLC	$89.3M	3,822,579
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$88.3M	3,779,900
Eversept Partners, LP	$67.4M	2,885,622
KINGDON CAPITAL MANAGEMENT, L.L.C.	$58.4M	2,500,000
Hood River Capital Management LLC	$55.0M	2,354,285

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SNDX on your watchlist

Track score changes the day Syndax Pharmaceuticals Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SNDX a good stock to buy?

13F Pro's AI-powered analysis of Syndax Pharmaceuticals Inc (SNDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNDX are available on the SNDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SNDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Syndax Pharmaceuticals Inc's investment landscape.